In this episode Dr Moira Murphy the Research Director for the charity Diabetes UK and Professor Mark McCarthy a world leading Type 2 geneticist who worked in London and Oxford talk to Andrew and Maggie. They describe how, under Moira’s leadership, 6 centres in the UK (Exeter, Oxford, Imperial, Royal London, Newcastle and Norwich/Cambridge) worked together and become world leading in describing the genetic changes that make you more likely to develop Type 2 diabetes. The first major breakthrough was in 2007 when they published one of the very first genomewide association scans for Type 2 diabetes
This is the paper that was published in Science in April 2007.
https://pubmed.ncbi.nlm.nih.gov/17463249/
More about today’s guests
Dr Moira Murphy
Dr Moira Murphy was the research director of Diabetes UK between 1989 and 2003 although before 2000 this charity was called the British Diabetic Association (BDA). Moira was a scientist, who did a PhD after her degree. After initially working in the pharmaceutical industry she decided to take the post as the scientific director for the UK’s leading diabetes charity. In this post she led the research spending of the charity. She was fundamental in the decision to support the early work in the genetics of diabetes by funding, using the Warren bequest, the collection of blood to make DNA samples from people living with diabetes including Type 1 diabetes , Type 2 diabetes and monogenic diabetes. Her decision that all the UK groups working in Type 2 diabetes must work together if they were to receive funding was critical for the success of the UK research teams in genetics of Type 2 diabetes on the world stage
Professor Mark McCarthy
Professor Mark McCarthy trained as a doctor working in diabetes and endocrinology in Cambridge and London. In his final years of his medical training he went into research into the genetics of Type 2 diabetes, working with Prof. Graham Hitman (Royal London). A year spent in Boston USA with Eric Lander in the mid 90s was transformative to his approach to the genetics of complex disease like Type 2 diabetes. On his return to the UK, he took up a joint clinical and research post at Imperial College, London, and built a team working on the genetics of type 2 diabetes. In 2002 he moved to Oxford as Robert Turner Professor of Diabetic Medicine and stayed there till his move to take up the position of Senior Director in Human Genetics at Genentech in June 2019. Mark was an early pioneer in the genetics of Type 2 diabetes co-leading the collection of DNA from patients throughout the UK and leading the Type 2 diabetes component of the Wellcome Trust Case Consortium that published in 2007. He is a world leader in the genetics of complex disease and is one of the most cited scientists in diabetes.